Survo-Series
Every batch of Labrat Peptides undergoes third-party Mass Spectrometry and HPLC analysis. We believe in absolute transparency - since in third-party marketing we need complete confidence.
Survodutide 10MG is an investigational synthetic peptide research material supplied for controlled laboratory research, analytical testing, biochemical investigation, and scientific study.
Survodutide, also known as BI 456906, is an investigational dual glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist. Scientific research has investigated the compound's pharmacological activity at both receptors and its effects in preclinical and clinical research models. citeturn0search4turn0search5
Current clinical research has evaluated survodutide in obesity and metabolic research. A Phase 3 study published in the New England Journal of Medicine in June 2026 reported significantly greater body-weight reduction with survodutide than placebo in adults with obesity without diabetes. citeturn0search0turn0search2
LabRat Peptides supplies Survodutide 10MG as a Research Use Only (RUO) material for qualified research environments.
This product is not intended for human consumption, self-administration, therapeutic use, clinical treatment, diagnosis, disease prevention, veterinary use, or food applications.
Researchers can explore additional GLP Research Peptides and access scientific resources through the LabRat Peptides Research Hub.
Survodutide is an investigational peptide also identified by the development code BI 456906.
It has been developed as a dual GCGR/GLP-1R agonist, meaning that the molecule is designed to interact with both the glucagon receptor and GLP-1 receptor.
Research investigating survodutide has included:
A 2024 pharmacological study described the selection of survodutide from a group of dual GCGR/GLP-1R agonists based on its balanced receptor activity and preclinical pharmacological profile. citeturn0search4
Researchers can review the scientific literature through PubMed – Survodutide Research.
Survodutide research spans receptor pharmacology, metabolic biology, peptide research, and clinical investigation.
Potential laboratory research areas include:
The specific use of the research material should be determined by qualified researchers according to their approved research protocols and applicable laboratory requirements.
Survodutide has been investigated as a dual GLP-1 receptor and glucagon receptor agonist.
Unlike selective GLP-1 receptor research compounds, survodutide is designed to engage both receptor systems. Research has examined receptor activity using cellular assays and animal models to characterize its pharmacological profile. citeturn0search4
Researchers studying survodutide may therefore investigate:
Laboratory studies can examine the interaction of peptide compounds with GLP-1 receptor signaling pathways.
Survodutide's glucagon receptor activity makes it relevant to research involving GCGR signaling and downstream metabolic pathways.
The combined receptor activity provides a research model for studying dual agonist pharmacology.
Researchers can evaluate peptide identity, purity, molecular characteristics, and analytical properties using appropriate laboratory techniques.
Preclinical research has investigated survodutide in relation to metabolic pathways, including glucose regulation, body-weight biology, energy intake, and energy expenditure.
A 2026 PubMed-indexed study examined the central actions of survodutide and reported experimental findings involving GLP-1R and GCGR expression, neuronal activation, food intake, and body-weight effects in animal models. citeturn0search3
These findings provide a basis for further laboratory investigation but should not be interpreted as evidence of a clinical effect outside the specific research conditions studied.
For researchers interested in the broader literature, see PubMed – Survodutide.
Survodutide has progressed beyond early preclinical research into controlled clinical trials.
A Phase 2 randomized, double-blind study evaluated survodutide in adults with overweight or obesity without diabetes over 46 weeks. The study investigated several once-weekly dose groups and reported dose-dependent reductions in body weight, with gastrointestinal adverse events being the most frequently reported category. citeturn0search5
More recently, the Phase 3 SYNCHRONIZE-1 study was published in the New England Journal of Medicine in June 2026. The trial included 725 adults with obesity without diabetes and evaluated once-weekly survodutide at doses adjusted up to 3.6MG or 6.0MG compared with placebo. citeturn0search0
The study reported mean body-weight changes at week 76 of approximately:
Gastrointestinal symptoms were the most common adverse events reported in the trial. citeturn0search0
These clinical findings are presented here solely as scientific background and should not be interpreted as a recommendation for human use of the research material.
Researchers can review the published study through the New England Journal of Medicine – Survodutide Study.
| Specification | Details |
|---|---|
| Product Name | Survodutide 10MG |
| Alternative Name | BI 456906 |
| Product Type | Synthetic Research Peptide |
| Quantity | 10MG |
| Research Classification | Research Use Only |
| Primary Research Area | GLP-1 / Glucagon Receptor Research |
| Research Applications | Biochemical and analytical research |
| Form | Lyophilized research material where applicable |
The exact molecular specifications, purity, peptide sequence, molecular weight, and analytical results should be confirmed against the batch-specific Certificate of Analysis (COA).
Quality verification is an important consideration when selecting Survodutide research material.
Researchers should review the analytical documentation associated with the exact product batch before incorporating the material into a laboratory workflow.
Depending on the applicable testing program, research peptide characterization may include:
The product label, batch number, and COA should correspond to the same research material.
For additional research materials, visit the LabRat Peptides Research Peptides Collection.
A Certificate of Analysis (COA) provides important batch-specific information about research-material identity and analytical testing.
Researchers should review the COA corresponding to their specific Survodutide 10MG batch.
Depending on the analytical program, a COA may include:
For accurate research documentation, retain the applicable COA with the corresponding product batch.
Survodutide 10MG should be stored and handled according to the specific product documentation and applicable batch COA.
Researchers should consider the requirements associated with:
If supplied as a lyophilized research material, follow the product-specific storage instructions and avoid unnecessary exposure to environmental conditions.
For additional educational information, visit the LabRat Peptides Research Hub.
Researchers can also read Understanding Lyophilized Research Materials for general laboratory-storage information.
Survodutide 10MG should be handled only by qualified personnel in an appropriate laboratory environment.
Researchers should follow their institution's safety procedures, applicable regulations, laboratory risk assessments, and product-specific handling requirements.
General laboratory practices may include:
For additional educational resources, visit the LabRat Peptides Research Hub.
Researchers interested in Survodutide can access peer-reviewed scientific literature through several authoritative databases.
Search published research using PubMed – Survodutide.
Researchers can also search the development code through PubMed – BI 456906.
The 2026 Phase 3 obesity study is available through the New England Journal of Medicine.
The Phase 3 SYNCHRONIZE-1 study is registered as NCT06066515. Researchers can review the study record through ClinicalTrials.gov.
These external scientific resources provide independent information for researchers conducting literature reviews and scientific investigations.
Survodutide 10MG is supplied strictly for laboratory research and analytical investigation.
This material is not intended for:
Researchers and institutions are responsible for ensuring that research materials are handled and used according to applicable laws, regulations, institutional requirements, laboratory procedures, and approved research protocols.
Survodutide, also known as BI 456906, is an investigational peptide designed to act as a dual glucagon receptor and GLP-1 receptor agonist. citeturn0search4
Survodutide 10MG is a 10MG research-material presentation intended for controlled laboratory research, analytical testing, and scientific investigation.
Survodutide has been characterized as a dual agonist of the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R). citeturn0search4
Research has investigated survodutide in areas including receptor pharmacology, metabolic biology, obesity, glucose regulation, and liver-related metabolic research. citeturn0search3turn0search5
Survodutide remains an investigational compound. Although Phase 3 clinical research has now been published, the research status should not be confused with general authorization for use. citeturn0search0
Yes. Survodutide has been evaluated in Phase 2 and Phase 3 clinical research. The 2026 SYNCHRONIZE-1 trial was published in the New England Journal of Medicine. citeturn0search0turn0search5
No. The LabRat Peptides product is supplied strictly as Research Use Only material and is not intended for human or veterinary use.
Researchers can review peer-reviewed publications through PubMed, the Phase 3 study through NEJM, and clinical-trial information through ClinicalTrials.gov.
Additional laboratory materials can be explored through the LabRat Peptides Research Peptides Collection.
Visit the LabRat Peptides Research Hub for educational content relating to research peptides, laboratory safety, storage, handling, and scientific investigation.
Researchers interested in Survodutide research, GLP-1 research peptides, glucagon receptor research, dual receptor agonists, metabolic research, peptide characterization, and laboratory research materials can explore the complete LabRat Peptides Research Peptides Collection.
For educational resources, visit the Research Hub.
For information about lyophilized research materials, read Understanding Lyophilized Research Materials.
FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.
Survodutide 10MG is supplied as a laboratory research material for scientific investigation, analytical testing, and biochemical research. It is not intended for human consumption, self-administration, therapeutic use, clinical treatment, diagnosis, prevention of disease, veterinary use, cosmetic use, or food applications.
The scientific information presented on this page summarizes published research and should not be interpreted as a recommendation, therapeutic claim, or statement that this research material is approved for human use.
| Sequence | Available on COA |
| Appearance | White Lyophilized Powder |
| Mol. Weight | 1419.6 g/mol |
| Purity | 99.2% |
| Storage | -20°C or below |
All peptides and research chemicals sold on this site are intended exclusively for in-vitro laboratory research. They are not approved for human consumption, medical treatment, veterinary use, or any in-vivo application.
